<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455452</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-9GY</org_study_id>
    <nct_id>NCT03455452</nct_id>
  </id_info>
  <brief_title>An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer</brief_title>
  <official_title>A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma in Second or Third Line Setting in Real Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a French, nationwide, prospective, observational, multi-center study in participants
      diagnosed with renal cell carcinoma, who start a new systemic therapy with nivolumab for the
      first time and within the market authorization approval, following a first or second-line
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">January 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (BORR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of socio-demographic characteristics in adult patients with advanced Renal Cell Carcinoma (RCC)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Socio-demographic characteristics will be summarized using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of clinical characteristics in adult patients with advanced Renal Cell Carcinoma (RCC)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Clinical characteristics will be summarized using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of treatment patterns in adult patients with advanced Renal Cell Carcinoma (RCC)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Treatment patterns will be evaluated using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of treatment-related Adverse Events (AE)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memorial Sloan Kettering Cancer Center (MSKCC) score</measure>
    <time_frame>At baseline</time_frame>
    <description>Questionnaire to determine overall survival based on clinical and laboratory data in metastatic RCC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score</measure>
    <time_frame>At baseline</time_frame>
    <description>Questionnaire to determine overall survival based on clinical and laboratory data in metastatic RCC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of incidence of treatment-related Adverse Events (AE)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of severity of treatment-related Adverse Events (AE)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) scores (EQ-5D utility)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) scores (FKSI-19)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>The FKSI-19 will be graded by the patient on a scale from 0 to 4 (range &quot;not at all to very much&quot;)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">323</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Renal Cell Cancer</condition>
  <condition>Adenocarcinoma Of Kidney</condition>
  <condition>Adenocarcinoma, Renal Cell</condition>
  <condition>Kidney Cancer</condition>
  <condition>Cancer of the Kidney</condition>
  <arm_group>
    <arm_group_label>Renal Cell Carcinoma (RCC) Participants</arm_group_label>
    <description>Participants diagnosed with advanced RCC and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Renal Cell Carcinoma (RCC) Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients who are at least 18 of age at the time of the treatment decision with the
        diagnosis of advanced RCC (histologically or cytologically confirmed) and whose physician
        has already decided to initiate a treatment with nivolumab for the first time for the
        treatment of RCC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with the diagnosis of advanced RCC (histologically or cytologically)
             whose physician has already decided to initiate a treatment with nivolumab as second
             or third line therapy for the first time for the treatment of RCC, according to the
             label approved in France

        Exclusion Criteria:

          -  Patients with a primary diagnosis of a cancer other than advanced RCC within the past
             five years, ie, a cancer other than RCC that requires systemic or other treatment

          -  Patients previously treated with anti-PD1, anti-PDL1 or anti-CTLA4 therapy

          -  Patients currently included in an interventional clinical trial for their advanced or
             RCC. Patients who have completed their participation in an interventional trial; or
             who are not receiving study drug anymore and who are only followed-up for OS can be
             enrolled

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

